2026 Investor Day: CRDMO model capturing next-gen growth

PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE MORE REPORTS FROM BLOOMBERG: RESP CMBR <GO> OR http://www.cmbi.com.hk 1 MN 9 Nov 2026 CMB International Global Markets | Equity Research | Company Update WuXi AppTec (603259 CH) WuXi AppTec (603259 CH) - 2026 Investor Day: CRDMO model capturing next-gen growth 2026 Investor Day: CRDMO model capturing next-gen growth WuXi AppTec (WXAP) held its 2026 Investor Day on 6 Nov. Mgmt. indicated its CRDMO business model will continue to generate a robust pipeline of high-quality projects, supporting the sustainable growth of its Chemistry segment and the Company overall. Mgmt. also highlighted opportunities in the rising AIDD trend, reinforcing Biology segment as a core gateway to its downstream businesses.  CRDMO model continuing to generate a robust pipeline of high-potential projects. Leveraging the world’s largest early-stage drug R&D platform, WXAP is deeply embedded in the frontier of global innovative drug R&D and has used its large-scale manufacturing capacity to support the production of several global blockbuster drugs. It manufactured seven of the top 10 best-selling chemically-synthetized drugs globally in 2025, driving the Company’s near-term growth. At the same time, it participated in seven of 10 2025 Molecules of the Year nominees, laying a solid foundation for sustained access to commercially attractive molecules. Specifically, WXAP manufactures three of the nine globally approved GLP-1 molecules, as well as three of the seven approved molecules in the KRAS space. Its scale in early-stage drug R&D allows a broad participation in global innovative drug programs and provides valuable industry insights. Such visibility supports proactive capacity planning and enables WXAP to capture opportunities as they arise, particularly in more complex modalities such as peptides, cyclic peptides and molecular glues. Mgmt. is confident that its CRDMO model will continue to produce a robust and promising pipeline, enabling WXAP to rapidly ramp up new capacity to convert bookings into revenue and profit.  AIDD to widen R&D funnel and create incremental business for CRDMO model. Mgmt. believes AI-driven drug discovery (AIDD) can expand drug discovery demand and project funnel. For instance, one leading AIDD company requires DMPK assay throughput up to 50 times that of a traditional biotech. AI is expected to generate deeper biological insights, accelerate new program launches, and enable more new modalities, thereby bringing new deal flow into early research. AI-native customers need both data to optimize models and execution to advance pipelines. WXAP can meet the demand of such customers with an established capability of a wet-dry closed loop. Because all drug R&D development remains subject to current regulatory standards, WXAP can also capture translation needs from in vitro to in vivo and from discovery through development down the road. Although AIDD-related bus